These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20816372)

  • 1. Safety of denosumab in giant-cell tumour of bone.
    Thomas D; Carriere P; Jacobs I
    Lancet Oncol; 2010 Sep; 11(9):815. PubMed ID: 20816372
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of denosumab in giant-cell tumour of bone.
    Kyrgidis A; Toulis K
    Lancet Oncol; 2010 Jun; 11(6):513-4. PubMed ID: 20522379
    [No Abstract]   [Full Text] [Related]  

  • 3. Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.
    Fusco V; Galassi C; Berruti A; Ciuffreda L; Ortega C; Ciccone G; Angeli A; Bertetto O
    J Clin Oncol; 2011 Jun; 29(17):e521-2; author reply e523-4. PubMed ID: 21537047
    [No Abstract]   [Full Text] [Related]  

  • 4. Denosumab: a breakthrough in treatment of giant-cell tumour of bone?
    Balke M; Hardes J
    Lancet Oncol; 2010 Mar; 11(3):218-9. PubMed ID: 20149737
    [No Abstract]   [Full Text] [Related]  

  • 5. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
    Thomas D; Henshaw R; Skubitz K; Chawla S; Staddon A; Blay JY; Roudier M; Smith J; Ye Z; Sohn W; Dansey R; Jun S
    Lancet Oncol; 2010 Mar; 11(3):275-80. PubMed ID: 20149736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab for bone metastases from breast cancer: a new therapy option?
    Aapro MS
    J Clin Oncol; 2011 May; 29(14):e419-20; author reply e421-4. PubMed ID: 21464408
    [No Abstract]   [Full Text] [Related]  

  • 7. More about osteonecrosis.
    Finkelman RD; Clemons M; Bouganim N
    J Am Dent Assoc; 2011 Apr; 142(4):371-2; author reply 372-4. PubMed ID: 21454842
    [No Abstract]   [Full Text] [Related]  

  • 8. Denosumab-related osteonecrosis of the jaws.
    Kyrgidis A; Toulis KA
    Osteoporos Int; 2011 Jan; 22(1):369-70. PubMed ID: 20306021
    [No Abstract]   [Full Text] [Related]  

  • 9. A new class of drugs to prevent osteoporosis may be associated with osteonecrosis of the jaw.
    Wynn RL
    Gen Dent; 2011; 59(1):10-2. PubMed ID: 21613033
    [No Abstract]   [Full Text] [Related]  

  • 10. Osteonecrosis of jaw with the use of denosumab.
    Akhtar NH; Afzal MZ; Ahmed AA
    J Cancer Res Ther; 2011; 7(4):499-500. PubMed ID: 22269422
    [No Abstract]   [Full Text] [Related]  

  • 11. RANKL, denosumab, and giant cell tumor of bone.
    Thomas DM
    Curr Opin Oncol; 2012 Jul; 24(4):397-403. PubMed ID: 22581354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New oncology drugs and osteonecrosis of the jaw (ONJ).
    Migliorati CA; Covington JS
    J Tenn Dent Assoc; 2009; 89(4):36-8; quiz 38-9. PubMed ID: 20102031
    [No Abstract]   [Full Text] [Related]  

  • 13. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
    Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab: Excellent response of metastatic giant cell tumor of the bone.
    Ulas A; Bulent Akinci M; Silay K; Sendur MA; Sener Dede D; Yalcin B
    J BUON; 2015; 20(2):666-7. PubMed ID: 26011370
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
    Chawla S; Henshaw R; Seeger L; Choy E; Blay JY; Ferrari S; Kroep J; Grimer R; Reichardt P; Rutkowski P; Schuetze S; Skubitz K; Staddon A; Thomas D; Qian Y; Jacobs I
    Lancet Oncol; 2013 Aug; 14(9):901-8. PubMed ID: 23867211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab: a new treatment option for giant cell tumor of bone.
    Lewin J; Thomas D
    Drugs Today (Barc); 2013 Nov; 49(11):693-700. PubMed ID: 24308016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
    Gossai N; Hilgers MV; Polgreen LE; Greengard EG
    Pediatr Blood Cancer; 2015 Jun; 62(6):1078-80. PubMed ID: 25556556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone.
    Demirsoy U; Karadogan M; Selek Ö; Anik Y; Aksu G; Müezzinoglu B; Corapcioglu F
    J Pediatr Hematol Oncol; 2014 Mar; 36(2):156-8. PubMed ID: 24072245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab for bone metastases.
    Med Lett Drugs Ther; 2011 Jan; 53(1356):8. PubMed ID: 21252843
    [No Abstract]   [Full Text] [Related]  

  • 20. Denosumab an option for patients with bone metastasis from breast cancer.
    Barton MK
    CA Cancer J Clin; 2011; 61(3):135-6. PubMed ID: 21532096
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.